Hisahide Nishio
Overview
Explore the profile of Hisahide Nishio including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
168
Citations
1279
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Kimizu T, Ida S, Oki K, Shima M, Nishimoto S, Nakajima K, et al.
Brain Dev
. 2023 Mar;
45(7):363-371.
PMID: 36973114
Objective: This study aimed to establish an optional newborn screening program for spinal muscular atrophy (SMA-NBS) in Osaka. Methods: A multiplex TaqMan real-time quantitative polymerase chain reaction assay was used...
12.
Nishio H
Lancet Child Adolesc Health
. 2023 Jan;
7(3):146-147.
PMID: 36669517
No abstract available.
13.
Noguchi Y, Bo R, Nishio H, Matsumoto H, Matsui K, Yano Y, et al.
Genes (Basel)
. 2022 Nov;
13(11).
PMID: 36421785
Spinal muscular atrophy (SMA) is a common devastating neuromuscular disorder, usually involving homozygous deletion of the gene. Newly developed drugs can improve the motor functions of infants with SMA when...
14.
Okamoto K, Nishio H, Motoki T, Jogamoto T, Aibara K, Kondo Y, et al.
Int J Neonatal Screen
. 2022 Oct;
8(4).
PMID: 36278622
Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder. Al-though there was no cure for SMA, newly developed therapeutic drugs (nusinersen, onasemnogene abeparvovec, and risdiplam) have been proven effective...
15.
Maeta K, Farea M, Nishio H, Matsuo M
Int J Mol Sci
. 2022 May;
23(9).
PMID: 35563408
Antisense oligonucleotides (ASOs) are agents that modulate gene function. ASO-mediated out-of-frame exon skipping has been employed to suppress gene function. Myostatin, encoded by the gene, is a potent negative regulator...
16.
Farea M, Maeta K, Nishio H, Matsuo M
Front Cell Dev Biol
. 2022 May;
10:877612.
PMID: 35547811
Dystrophin Dp71 is an isoform produced from the Dp71 promoter in intron 62 of the gene, mutations in which cause Duchenne muscular dystrophy. Dp71 is involved in various cellular processes...
17.
Wijaya Y, Niba E, Nishio H, Okamoto K, Awano H, Saito T, et al.
Genes (Basel)
. 2022 Apr;
13(4).
PMID: 35456491
Spinal muscular atrophy (SMA) is caused by deletion. The encodes the same protein as does, but it has a splicing defect of exon 7. Some antisense oligonucleotides (ASOs) have been...
18.
Shirakawa T, Ikushima A, Maruyama N, Nambu Y, Awano H, Osawa K, et al.
Animal Model Exp Med
. 2022 Mar;
5(1):48-55.
PMID: 35229992
The mdx mouse is a model of Duchenne muscular dystrophy (DMD), a fatal progressive muscle wasting disease caused by dystrophin deficiency, and is used most widely in preclinical studies. Mice...
19.
Niba E, Nishio H, Wijaya Y, Ar Rochmah M, Takarada T, Takeuchi A, et al.
Genes (Basel)
. 2022 Feb;
13(2).
PMID: 35205250
Spinal muscular atrophy (SMA) is a common autosomal recessive neuromuscular disease characterized by defects of lower motor neurons. Approximately 95% of SMA patients are homozygous for () gene deletion, while...
20.
Yamadera M, Saito T, Shinohara M, Nishio H, Murayama S, Fujimura H
Neuropathology
. 2022 Feb;
42(2):141-146.
PMID: 35144320
Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disease characterized by progressive muscle weakness due to degeneration of lower motor neurons in the anterior horn of the spinal cord....